Abstract 1733P
Background
On 24th of February 2022 reality in Ukraine changed. Ukraine became a victim of unfair attack of the neighbouring county. It influenced civilian population hugely, including the most vulnerable - children, elderly and patients. Since then, cancer patients became fighters of two fights - malignant disease and external aggressor. After more than a year of this reality Ukrainian oncologists would like to remind international society that the problem is not solved, and Ukrainians desperately need support.
Methods
It is generalized description of situation in the sphere of oncology in Ukraine since 24th of February 2022.
Results
According to Ukraine's Minister of Health, Victor Lyashko, during the first year of the war in Ukraine 1218 hospitals were damaged, 540 - partially destroyed and 173 destroyed completely. Among them - oncological hospitals. More than a million (∼1.2) Ukrainians currently stay on temporary occupied territories of the country and do not have access to qualified medical care. Around 7 million people had to move to safer areas of the country to stay safe and thousands of cancer patients had to move abroad for further treatment. It influenced the oncological landscape significantly. Oncological centers currently have to deal with 70% more patients than before the war. Moreover, the quantity of advanced stage disease has risen dramatically because a lot of people just couldn’t get medical help in time. Therefore, it caused bigger pressure on the medical system, requiring even more resources when they are so limited. At the same time, all clinical trials were put on pause leaving patients with advanced and rare diseases with no options for further treatment. Luckily, international society is extremely friendly to Ukraine providing Ukrainians with shelters and supplies, both material and intellectual. It helped and is helping a lot. But unfortunately, war is not over, and help is still needed.
Conclusions
The aim of the work is to show how things were going during this year of war and how they are actually going now for word to realize that even during the hardest time there is a place for high quality medical care. That only became possible thanks to huge support of international society, but there is still a lot to do to rebuild and improve reality that was destroyed on 24th of February.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23